New York State Practitioner Education Medical Use of Marijuana 2-hr Required Course

New York State Practitioner Education Medical Use of Marijuana 2-hr Required Course

You are not logged in. Only partial content from this topic will be available to you. To view the full content, you must log in to your account. Don't have a login? Register now. Or, check out our Preview.

Section 1.0: The Endocannabinoid System and Phytocannabinoids


Part 3

 

The Pharmacological Properties of the Minor Phytocannabinoids

 

The extent to which the minor phytocannabinoids, including cannabichromene (CBC), cannabigerol (CBG), tetrahydrocannabivarin (THCV), and cannabinol (CBN), have been studied pales in comparison to that of the major phytocannabinoids. Clinical research involving these minor phytocannabinoids is lacking.



Quiz icon Take a quiz related to this syllabus topic.

Cannabichromene (CBC) was first discovered in 1966. Since that time, the pharmacological properties of cannabichromene have been investigated. How does (CBC) interact with the endocannabinoid system?

Similar to cannabichromene (CBC), cannabigerol (CBG) has been subject to relatively few scientific studies since its discovery in 1964. How does CBG interact with the endocannabinoid system?

How does tetrahydrocannabivarin (THCV) interact with the endocannabinoid system?

Scientists first isolated cannabinol in 1896, yet there are relatively few published papers in the scientific literature specific to cannabinol (CBN).  Cannabinol is the oxidative by-product of THC and appears after long storage (8). How does cannabinol interact with the endocannabinoid system?